Zhejiang Taimei Medical Technology (HKG:2576) forecasts its net loss to narrow by 38% to 220 million yuan in 2024 from 356.4 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.
The lower loss forecast is attributable to a higher overall gross profit margin and a decline in selling and research and development costs, the filing said.
The medical technology company plans to publish its annual results by the end of March.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。